- Home
- BRT vs CADL Comparison
BRT vs CADL Comparison
Compare BRT & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- CADL
- Stock Information
- Founded
- BRT 1972
- CADL 1999
- Country
- BRT United States
- CADL United States
- Employees
- BRT N/A
- CADL N/A
- Industry
- BRT Real Estate Investment Trusts
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- CADL Health Care
- Exchange
- BRT Nasdaq
- CADL Nasdaq
- Market Cap
- BRT 291.9M
- CADL 252.0M
- IPO Year
- BRT N/A
- CADL 2021
- Fundamental
- Price
- BRT $16.19
- CADL $5.12
- Analyst Decision
- BRT Strong Buy
- CADL Strong Buy
- Analyst Count
- BRT 1
- CADL 5
- Target Price
- BRT $21.00
- CADL $21.40
- AVG Volume (30 Days)
- BRT 30.3K
- CADL 923.9K
- Earning Date
- BRT 08-05-2025
- CADL 08-12-2025
- Dividend Yield
- BRT 6.18%
- CADL N/A
- EPS Growth
- BRT N/A
- CADL N/A
- EPS
- BRT N/A
- CADL N/A
- Revenue
- BRT $98,162,000.00
- CADL N/A
- Revenue This Year
- BRT $0.36
- CADL N/A
- Revenue Next Year
- BRT $5.65
- CADL N/A
- P/E Ratio
- BRT N/A
- CADL N/A
- Revenue Growth
- BRT 2.71
- CADL N/A
- 52 Week Low
- BRT $14.61
- CADL $3.79
- 52 Week High
- BRT $20.22
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- BRT 56.13
- CADL 48.58
- Support Level
- BRT $15.53
- CADL $4.73
- Resistance Level
- BRT $15.99
- CADL $5.24
- Average True Range (ATR)
- BRT 0.40
- CADL 0.29
- MACD
- BRT 0.01
- CADL 0.00
- Stochastic Oscillator
- BRT 87.65
- CADL 64.92
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.